Efficacy and Safety of Pharmacological Interventions in Managing Cardiometabolic Risk Factors in Youth Living with Overweight and Obesity: A Systematic Review and Network Meta-Analysis.

Faghfouri AH, Musazadeh V, Mokari-Yamchi A, Faramarzi F, Pam P, Shekari S, Mahmoudzadeh M, Gheibi S

Obesity reviews : an official journal of the International Association for the Study of Obesity28 May 2025Cited by 2 (Europe PMC)

PMID40437653DOI10.1111/obr.13946PepBankPUB-40437653

Publisher page PubMedAsk about this study

Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

1 result from studies that gave the peptide. 1 result from people.

01HumanSystematic reviewEfficacy outcome
In reviewed youth aged 2–20 with overweight/obesity, liraglutide improved FBG (MD-11.00 mg/dL,95% CI -20.38 to-1.62); placebo is named as comparator in the source conclusion, and native analyzed N was unstated.
In plain wordsIn reviewed young people with overweight/obesity, liraglutide lowered fasting glucose versus placebo.
Peptide
Liraglutide
Outcome
DecreaseFasting blood glucose
Study
n: not reported in source
Comparator
placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated
Measurements
FBG MD
−11 mg/dL
native liraglutide; placebo reference stated in conclusion
95% CI
−20.38 to −1.62 mg/dL
FBG MD
Source sentences
Summary
Orlistat (MD = -1.81 mmHg; 95% CI: -2.94, -0.68), metformin (MD: -0.14 unit; 95%CI: -0.23 to -0.04), liraglutide (MD: -11.00 mg/dL; 95% CI: -20.38 to -1.62) were more effective in improving DBP, BMI-z score, and FBG, respectively.
4 context sentences(design, population, supporting numbers)
Summary · context
We conducted a comprehensive literature search on PubMed, Scopus, Embase, Web of Science, and the Cochrane Library, covering studies published up to September 2024.
Summary · context
Randomized clinical trials (RCTs) were included if they reported efficacy of weight-loss medications in youth populations aged 2-20 years.
Summary · context
Direct and indirect evidence were synthesized using a frequentist framework.
Summary · context
Liraglutide and metformin result in a significant reduction in FBG levels compared to placebo.
Report a problemFND-4043765301

Studies that did not test the peptide alone2

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

02HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In reviewed youth aged 2–20 with overweight/obesity, lipid profile was reported unaffected across studied drugs including liraglutide; no original contrast, signed coefficient or statistical test was stated.
In plain wordsIn reviewed young people with overweight/obesity, pooled drugs including liraglutide reportedly did not affect blood lipids; the comparison and test were unstated.
Peptide
Liraglutide
Outcome
Direction not reportedLipid profile
Study
n: not reported in source
Outcome group
Lipids · Metabolic and weight
Source sentences
Summary
Lipid profile and SBP were not affected by studied drugs.
3 context sentences(design, population, supporting numbers)
Summary · context
We conducted a comprehensive literature search on PubMed, Scopus, Embase, Web of Science, and the Cochrane Library, covering studies published up to September 2024.
Summary · context
Randomized clinical trials (RCTs) were included if they reported efficacy of weight-loss medications in youth populations aged 2-20 years.
Summary · context
Direct and indirect evidence were synthesized using a frequentist framework.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4043765302
03HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In reviewed youth aged 2–20 with overweight/obesity, systolic blood pressure was reported unaffected across studied drugs including liraglutide; no original contrast, signed coefficient or statistical test was stated.
In plain wordsIn reviewed young people with overweight/obesity, pooled drugs including liraglutide reportedly did not affect systolic blood pressure; the comparison and test were unstated.
Peptide
Liraglutide
Outcome
Direction not reportedSystolic blood pressure
Study
n: not reported in source
Outcome group
Blood pressure · Cardiovascular
Source sentences
Summary
Lipid profile and SBP were not affected by studied drugs.
3 context sentences(design, population, supporting numbers)
Summary · context
We conducted a comprehensive literature search on PubMed, Scopus, Embase, Web of Science, and the Cochrane Library, covering studies published up to September 2024.
Summary · context
Randomized clinical trials (RCTs) were included if they reported efficacy of weight-loss medications in youth populations aged 2-20 years.
Summary · context
Direct and indirect evidence were synthesized using a frequentist framework.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4043765303

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.